AngioDynamics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jim Clemmer

Chief executive officer

US$4.0m

Total compensation

CEO salary percentage	19.0%
CEO tenure	8yrs
CEO ownership	1.0%
Management average tenure	5.8yrs
Board average tenure	8.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jim Clemmer's remuneration changed compared to AngioDynamics's earnings?
Date	Total Compensation	Salary	Company Earnings
Feb 29 2024	n/a	n/a	-US$192m
Nov 30 2023	n/a	n/a	-US$14m
Aug 31 2023	n/a	n/a	US$6m
May 31 2023	US$4m	US$756k	-US$52m
Feb 28 2023	n/a	n/a	-US$37m
Nov 30 2022	n/a	n/a	-US$33m
Aug 31 2022	n/a	n/a	-US$33m
May 31 2022	US$6m	US$736k	-US$27m
Feb 28 2022	n/a	n/a	-US$40m
Nov 30 2021	n/a	n/a	-US$38m
Aug 31 2021	n/a	n/a	-US$34m
May 31 2021	US$4m	US$720k	-US$32m
Feb 28 2021	n/a	n/a	-US$169m
Nov 30 2020	n/a	n/a	-US$171m
Aug 31 2020	n/a	n/a	-US$170m
May 31 2020	US$3m	US$716k	-US$167m
Feb 29 2020	n/a	n/a	-US$7m
Nov 30 2019	n/a	n/a	-US$6m
Aug 31 2019	n/a	n/a	-US$7m
May 31 2019	US$3m	US$687k	-US$11m
Feb 28 2019	n/a	n/a	-US$34m
Nov 30 2018	n/a	n/a	-US$16m
Aug 31 2018	n/a	n/a	-US$12m
May 31 2018	US$3m	US$643k	-US$6m
Feb 28 2018	n/a	n/a	US$1m
Nov 30 2017	n/a	n/a	-US$10m
Aug 31 2017	n/a	n/a	US$4m
May 31 2017	US$2m	US$625k	-US$7m

Compensation vs Market: Jim's total compensation ($USD3.98M) is above average for companies of similar size in the German market ($USD691.02K).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.

CEO

Jim Clemmer (59 yo)

8yrs

Tenure

US$3,983,691

Compensation

Mr. James C. Clemmer, also known as Jim, has been the Chief Executive Officer, President and a Director of AngioDynamics, Inc. since joining it on April 04, 2016. Mr. Clemmer served as Group President of t...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Clemmer	CEO, President & Director	8yrs	US$3.98m	0.97% $ 2.1m
Stephen Trowbridge	Executive VP & CFO	4.5yrs	US$1.25m	0.22% $ 471.2k
Chad Campbell	Senior VP and GM of Global Vascular Access & Oncology Global Business Unit	7.9yrs	US$778.04k	0.087% $ 190.1k
Laura Piccinini	Senior VP & GM of International	2.8yrs	US$843.44k	0.0083% $ 18.1k
Saleem Cheeks	Vice President of Communications	4.2yrs	no data	no data
Benjamin Davis	Senior Vice President of Business Development	9.1yrs	no data	no data
Marna Bronfen-Moore	Senior Vice President of Human Resources	4.6yrs	no data	no data
Warren Nighan	Senior Vice President of Quality & Regulatory Affairs	7yrs	US$897.17k	no data
Kim Seabury	Senior Vice President of Information Technology	12.6yrs	no data	no data
Juan Serna	Senior Vice President of Scientific & Clinical Affairs	3.3yrs	no data	no data

5.8yrs

Average Tenure

55yo

Average Age

Experienced Management: UG2's management team is seasoned and experienced (5.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
James Clemmer	CEO, President & Director	8yrs	US$3.98m	0.97% $ 2.1m
Jan Reed	Independent Director	7.4yrs	US$224.50k	0.15% $ 324.6k
Wesley Johnson	Independent Director	17.3yrs	US$234.50k	0.25% $ 539.6k
Howard Donnelly	Independent Non-Executive Chairman	20.1yrs	US$262.00k	0.30% $ 661.4k
Eileen Auen	Independent Director	8.3yrs	US$224.50k	0.15% $ 322.8k
Michael Dake	Member of the Scientific Advisory Board	no data	no data	no data
Frank Veith	Member of the Scientific Advisory Board	no data	no data	no data
Thomas Sos	Member of the Scientific Advisory Board	no data	no data	no data
Stephen Kee	Member of the Scientific Advisory Board	no data	no data	no data
John Kaufman	Member of the Scientific Advisory Board	no data	no data	no data
Jacob Cynamon	Member of the Scientific Advisory Board	no data	no data	no data
Karen Licitra	Independent Director	4.8yrs	US$224.50k	0.11% $ 245.3k

8.1yrs

Average Tenure

62.5yo

Average Age

Experienced Board: UG2's board of directors are considered experienced (8.1 years average tenure).

AngioDynamics Management

Management criteria checks 3/4

Key information

Recent management updates

CEO, President & Director recently bought €62k worth of stock

Insufficient new directors

Angiodynamics, Inc. Announces Board Changes

AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023

AngioDynamics, Inc. Announces Addition of Lorinda Burgess to Board of Directors

Key Executive recently sold €55k worth of stock

Recent updates

New minor risk - Shareholder dilution

CEO, President & Director recently bought €62k worth of stock

Third quarter 2024 earnings released: US$4.73 loss per share (vs US$0.24 loss in 3Q 2023)

Insufficient new directors

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024

Angiodynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc

AngioDynamics, Inc. to Report Q3, 2024 Results on Apr 04, 2024

Angiodynamics, Inc. Announces Board Changes

Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease

AngioDynamics, Inc. Announces Manufacturing Operations Restructuring

AngioDynamics, Inc. to Report Q2, 2024 Results on Jan 05, 2024

AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary Embolism

New minor risk - Share price stability

Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024

First quarter 2024 earnings released: EPS: US$1.15 (vs US$0.33 loss in 1Q 2023)

AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023

AngioDynamics, Inc. to Report Q1, 2024 Results on Oct 04, 2023

AngioDynamics, Inc. Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

Angiodynamics, Inc. Completes Enrollment for Preserve Clinical Study

AngioDynamics, Inc. Announces Addition of Lorinda Burgess to Board of Directors

AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$1.33 loss per share (vs US$0.68 loss in FY 2022)

AngioDynamics, Inc. to Report Q4, 2023 Results on Jul 12, 2023

New minor risk - Profitability

Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million.

Forecast to breakeven in 2026

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.13 loss in 3Q 2022)

Key Executive recently sold €55k worth of stock

AngioDynamics, Inc. Reaffirms Revenue Guidance for Fiscal 2023

Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.21 loss in 2Q 2022)

AngioDynamics, Inc. to Report Q2, 2023 Results on Jan 05, 2023

Insufficient new directors

AngioDynamics, Inc. Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism

CEO, President & Director recently bought €155k worth of stock

First quarter 2023 earnings released: US$0.33 loss per share (vs US$0.18 loss in 1Q 2022)

AngioDynamics, Inc. Reaffirms Earnings Guidance for the Year 2023

AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022

AngioDynamics, Inc. to Report Q1, 2023 Results on Oct 06, 2022

Key Executive recently sold €110k worth of stock

Full year 2022 earnings released: US$0.68 loss per share (vs US$0.82 loss in FY 2021)

Forecast to breakeven in 2025

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2023

AngioDynamics, Inc. to Report Q4, 2022 Results on Jul 12, 2022

Key Executive recently sold €75k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.092 loss in 3Q 2021)

AngioDynamics, Inc. Provides Earnings Guidance for the Year 2022

CEO, President & Director recently bought €201k worth of stock

AngioDynamics, Inc. Reports Impairment for the Three Months Ended November 30, 2021

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

AngioDynamics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Key Executive recently sold €84k worth of stock

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021)

Full year 2021 earnings released: US$0.82 loss per share (vs US$4.39 loss in FY 2020)

Angiodynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2022

AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System

Key Executive recently sold €70k worth of stock

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.15 loss in 3Q 2020)

AngioDynamics, Inc. Revises Earnings Guidance for the Fiscal Year 2021

AngioDynamics, Inc. to Report Q3, 2021 Results on Mar 30, 2021

New 90-day high: €17.70

New 90-day high: €15.80

AngioDynamics, Inc. Announces Management Changes

Independent Director recently sold €100k worth of stock

Revenue beats expectations

Second quarter 2021 earnings released: US$0.11 loss per share

Revenue beats expectations

New 90-day high: €12.60